FY2024 Earnings Forecast for IN8bio Issued By HC Wainwright

IN8bio, Inc. (NASDAQ:INAB) – HC Wainwright issued their FY2024 earnings per share (EPS) estimates for IN8bio in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.59) for the year. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for IN8bio’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at $0.54 EPS.

IN8bio Price Performance

Shares of INAB opened at $0.34 on Friday. IN8bio has a 12-month low of $0.22 and a 12-month high of $2.48. The company has a current ratio of 1.84, a quick ratio of 2.66 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $15.69 million, a PE ratio of -0.45 and a beta of -0.07. The business’s 50 day moving average is $0.30 and its 200 day moving average is $0.67.

Hedge Funds Weigh In On IN8bio

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp boosted its stake in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 851,280 shares of the company’s stock after acquiring an additional 251,600 shares during the quarter. Sigma Planning Corp owned about 1.82% of IN8bio worth $230,000 as of its most recent SEC filing. Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.